Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02587715 : A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 60 Years
Eligibility
Main inclusion criteria: Males and Females between age 18 and 60 years with confirmed
diagnosis of Relapsing Remitting Multiple Sclerosis made by a neurology expert/MS expert
with lesions demonstrated on brain MRI that are consistent with MS and having an EDSS
(Kurtzke Expanded Disability Status Scale) score between 3.5 & 6

Inclusion Criteria:

- Males and Females between age 18 and 60 years

- Diagnosis of Relapsing Remitting Multiple Sclerosis made by a neurology expert/MS
expert with lesions demonstrated on brain MRI that are consistent with MS

- Duration of disease: >5 years

- Having an EDSS (Kurtzke Expanded Disability Status Scale) score between 3.5 & 6

- History of 2 or more relapses within last 2 years with increase in EDSS scale of >
0.5 sustained for > 4 weeks

- Failure to respond or intolerance to the currently available Multiple Sclerosis (MS)
immunomodulatory treatments): the lack of response to these treatments will be
determined/defined by history of 2 or more relapses within last 2 years with increase
in EDSS scale of > 0.5 sustained for > 4 weeks

- Must have proof of health insurance in country of residence

Exclusion Criteria:

- Primary progressive, secondary progressive or progressive relapsing MS as defined by
Lublin and Reingold, 1996. These conditions require the presence of continuous
clinical disease worsening over a period of at least 3 months. Subjects with these
conditions may also have superimposed relapses but are distinguished from relapsing
remitting subjects by the lack of clinically stable periods of clinical improvement.

- Unable to perform Timed 25-Foot Walk, 9 Hole Peg Test (HPT) (with both upper
extremities) and Paced Auditory Serial Addition Test (PASAT 3)

- Females who are pregnant or nursing or females of childbearing potential who are
unwilling to maintain contraceptive therapy for the duration of the study

- Life expectancy < 6 months due to concomitant illnesses

- Exposure to any investigational drug or procedure within 1 month prior to study entry
or enrolled in a concurrent study that may confound results of this study.

- Active infectious disease: For patients who have tested positive, an expert will be
consulted as to patient eligibility based on the patient's infectious status

- Any illness which, in the Investigator's judgment, will interfere with the patient's
ability to comply with the protocol, compromise patient safety, or interfere with the
interpretation of the study results

- Patients on chronic immunosuppressive transplant therapy

- Patients with unstable cardiac status (unstable angina, attack of myocardial
infarction within last 6 months, uncontrolled high blood pressure, hypotension,
cardiomyopathy)

- Cerebrovascular accident within 6 months prior to study entry

- Patients with poorly controlled diabetes mellitus

- Patients with renal insufficiency (Creatinine> 2.5) or failure

- Known drug or alcohol dependence or any other factors which will interfere with the
study conduct or interpretation of the results or who in the opinion of the
investigator is not suitable to participate.

- History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in
the last five years

- Unwilling and/or not able to give written informed consent.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02587715      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740